LYEL (Lyell Immunopharma) Moat Score: 4/10 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LYEL Lyell Immunopharma Inc LYEL
55 GF Score
Price $13.19
GF Value $5.26
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Lyell Immunopharma Moat Score?

Lyell Immunopharma LYEL +1.47% 55 Moat Score is 4 as of Jul. 22, 2026. GuruFocus rates LYEL with a GF Score™ of 55/100 and a GF Value™ of $5.26 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,396 Biotechnology companies, Lyell Immunopharma ranks better than 88.83% on this metric.

Lyell Immunopharma has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Lyell Immunopharma has Narrow Moat: Lyell Immunopharma has valuable intellectual property and patents in the biotech sector, providing some protection. However, it faces intense competition and lacks strong brand strength or significant customer switching costs, resulting in a modest moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Lyell Immunopharma might have Narrow Moat - Discernible but modest moat.

Lyell Immunopharma  (NAS:LYEL) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Lyell Immunopharma Moat Score Related Terms

LYEL vs ALXO, ARMP, NAGE: Moat Score Comparison

For the Biotechnology subindustry, Lyell Immunopharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lyell Immunopharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyell Immunopharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Lyell Immunopharma's Moat Score falls into.


LYEL
55GF Score
Lyell Immunopharma Inc LYEL
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Lyell Immunopharma (LYEL) has a Moat Score of 4 as of Jul. 22, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Lyell Immunopharma ranks #156 out of 1396 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Lyell Immunopharma's Moat Score too high?
Lyell Immunopharma's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Lyell Immunopharma's value of 4 is 100% above this industry median. Based on the distribution chart, Lyell Immunopharma ranks #156 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lyell Immunopharma has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lyell Immunopharma's Moat Score compare to ALXO and ARMP?
According to the Biotechnology industry distribution chart, Lyell Immunopharma ranks #156 out of 1396 companies for Moat Score. This places Lyell Immunopharma in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Lyell Immunopharma's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lyell Immunopharma's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lyell Immunopharma's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyell Immunopharma stock overvalued right now?
Based on GuruFocus' analysis, Lyell Immunopharma (LYEL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.26, compared to a current price of $13.19 — trading 150.8% above its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Lyell Immunopharma's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Lyell Immunopharma (LYEL), the current Moat Score is 4 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lyell Immunopharma (LYEL) Overvalued in 2026?

Based on GuruFocus' analysis, Lyell Immunopharma stock appears to be overvalued. The current stock price of $13.19 is trading 150.8% above its estimated GF Value™ of $5.26. GuruFocus considers Lyell Immunopharma to be Significantly Overvalued.

Key valuation signals for LYEL:

  • Moat Score: 4
  • GF Value™: $5.26 vs. price of $13.19 (150.8% above fair value)
  • GF Score™: 55/100 with 6 warning signs
  • Industry Position: 100% above the Biotechnology median (#156 of 1396)

No single metric tells the full story. See the LYEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lyell Immunopharma Business Description

Address 201 Haskins Way, South San Francisco, CA, USA, 94080
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
55GF Score

Get the complete analysis for LYEL

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.19
Price
$5.26
GF Value